Review
doi: 10.1159/000474402.
Quality of life of patients with advanced and metastatic prostatic carcinoma
Affiliations
- PMID: 8262116
- DOI: 10.1159/000474402
Item in Clipboard
Review
Quality of life of patients with advanced and metastatic prostatic carcinoma
Eur Urol.
1993.
Abstract
The quality of life of patients with advanced prostate cancer may be profoundly affected by local infiltration into adjacent organs and the occurrence of distant metastases. Secondary manifestations of advanced stages of prostate cancer include urinary retention, ureteric obstruction, rectal obstruction, chronic bone pain, compression of the spinal cord, hematological dysfunction and metabolic abnormalities. This review discusses the management of these patients in order to optimize their quality of life. Suitable palliative treatment for each secondary manifestation is recommended.
Similar articles
-
Manifestations of advanced prostate cancer: prognosis and treatment.J Urol. 1989 Oct;142(4):921-8. doi: 10.1016/s0022-5347(17)38943-7. J Urol. 1989. PMID: 2677414 Review. No abstract available.
-
Management of pain and other symptoms of advanced prostatic cancer.Semin Urol. 1988 Nov;6(4):311-21. Semin Urol. 1988. PMID: 3068769 Review. No abstract available.
-
The management of hormone-relapsed prostate cancer.BJU Int. 2003 Nov;92(8):860-8. doi: 10.1046/j.1464-410x.2003.04494.x. BJU Int. 2003. PMID: 14616436 Review. No abstract available.
-
Dilemmas in managing prostate carcinoma (Part II): Metastatic disease.Geriatrics. 1985 Sep;40(9):61-3, 67-70, 72. Geriatrics. 1985. PMID: 3896938
-
Palliative care in urology.Surg Clin North Am. 2011 Apr;91(2):429-44, x. doi: 10.1016/j.suc.2010.12.001. Surg Clin North Am. 2011. PMID: 21419262
Cited by
-
Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours.Clin Transl Oncol. 2014 Mar;16(3):322-9. doi: 10.1007/s12094-013-1077-2. Epub 2013 Aug 13. Clin Transl Oncol. 2014. PMID: 23943561 Free PMC article.
-
In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression.PLoS One. 2013;8(1):e53795. doi: 10.1371/journal.pone.0053795. Epub 2013 Jan 16. PLoS One. 2013. PMID: 23342005 Free PMC article.
-
Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.Int J Mol Sci. 2015 Dec 4;16(12):28943-78. doi: 10.3390/ijms161226138. Int J Mol Sci. 2015. PMID: 26690121 Free PMC article. Review.
-
Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer.PLoS One. 2013 Aug 19;8(8):e71637. doi: 10.1371/journal.pone.0071637. eCollection 2013. PLoS One. 2013. PMID: 23977098 Free PMC article.
-
Update in palliative management of hormone refractory cancer of prostate.Indian J Urol. 2007 Jan;23(1):43-50. doi: 10.4103/0970-1591.30266. Indian J Urol. 2007. PMID: 19675762 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical